Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Zevra Therapeutics (ZVRA) Depreciation & Amortization (IS) (2024 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Depreciation & Amortization (IS) for 2 consecutive years, with $362000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (IS) fell 78.03% year-over-year to $362000.0, compared with a TTM value of $4.0 million through Dec 2025, changed N/A, and an annual FY2025 reading of $4.1 million, down 36.55% over the prior year.
  • Depreciation & Amortization (IS) was $362000.0 for Q4 2025 at Zevra Therapeutics, down from $392000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (IS) topped out at $1.6 million in Q4 2024 and bottomed at $362000.0 in Q4 2025.